Sangamo’s (NASDAQ:SGMO) shares lost over a quarter of their value in the past two days, leaving investors at odds over when it will …
Sangamo Therapeutics (NASDAQ:SGMO) and TxCell announced this morning that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, …
Sangamo Therapeutics Inc (NASDAQ:SGMO) has just announced a strategic collaboration with Gilead Sciences, Inc’s (NASDAQ:GILD) company Kite, and shares are putting together a massive …
Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that the U.
Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced today key leadership appointments to strengthen the company’s clinical and commercial capabilities.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported its third quarter 2016 financial results and provided an update on recent events and development timelines for its therapeutic …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced today that the U.
Cowen analyst Ritu Baral was out with a favorable note on shares of Sangamo Biosciences, Inc. (NASDAQ:SGMO), after the biotech company released second-quarter results and provided …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), the leader in therapeutic genome editing, announced that the U.